Wei-Ming Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei-Ming Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Wen-Ting Dong
Heilongjiang Academy of Chinese Medicine Science, Institute of Chinese Materia Medica, Harbin, 15000, PR China
2 shared publicationsFeng-Jin Li
Heilongjiang Academy of Chinese Medicine, Institute of Chinese Materia Medica, Harbin, China
1 shared publicationGuo-Dong Sun
Heilongjiang Academy of Chinese Medicine, Institute of Chinese Materia Medica, Harbin, China
1 shared publicationJiang Pengna
Heilongjiang Academy of Chinese Medicine, Institute of Chinese Materia Medica, Harbin, China
1 shared publicationJin-Hai Huo
Heilongjiang Academy of Chinese Medicine, Institute of Chinese Materia Medica, Harbin, China
1 shared publication- Jinhai Huo
Heilongjiang Academy of Chinese Medicine Science, Institute of Chinese Materia Medica, Harbin, China, 150036
1 shared publication
Latest Publications
- Open Access
- 4 November 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
A Study Based on Metabolomics, Network Pharmacology, and Experimental Verification to Explore the Mechanism of Qinbaiqingfei Concentrated Pills in the treatment of Mycoplasma Pneumonia
Qinbaiqingfei concentrated pills (QB) are a commonly used medicine for the treatment of mycoplasma pneumonia in China, and the mechanism of action of QB needs to be studied further. Therefore, we use a combination of metabolomics and network pharmacology to clarify the mechanism of QB. Nontarget metabolomics studies were performed on rat serum, urine, and lung tissues, and 56 therapeutic biomarkers were found. Subsequently, the components of QB absorbed into the blood and lung tissues were clarified, and based on this finding, the core target of network pharmacology was predicted. The enrichment analysis of biomarkers–genes finally confirmed their close relationship with the NF-κB signaling pathway. By western blotting expression of the proteins in the lung tissue–related signaling pathways, it is finally confirmed that QB inhibits the NF-κB signaling pathway through SIRT1, IL-10 and MMP9, CTNNB1, EGFR, and other targets. It plays a role in regulating immunity, regulating metabolism, and treating diseases.
- 4 November 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessA Study Based on Metabolomics, Network Pharmacology, and Experimental Verification to Explore the Mechanism of Qinbaiqingfei Concentrated Pills in the treatment of Mycoplasma Pneumonia
Qinbaiqingfei concentrated pills (QB) are a commonly used medicine for the treatment of mycoplasma pneumonia in China, and the mechanism of action of QB needs to be studied further. Therefore, we use a combination of metabolomics and network pharmacology to clarify the mechanism of QB. Nontarget metabolomics studies were performed on rat serum, urine, and lung tissues, and 56 therapeutic biomarkers were found. Subsequently, the components of QB absorbed into the blood and lung tissues were clarified, and based on this finding, the core target of network pharmacology was predicted. The enrichment analysis of biomarkers–genes finally confirmed their close relationship with the NF-κB signaling pathway. By western blotting expression of the proteins in the lung tissue–related signaling pathways, it is finally confirmed that QB inhibits the NF-κB signaling pathway through SIRT1, IL-10 and MMP9, CTNNB1, EGFR, and other targets. It plays a role in regulating immunity, regulating metabolism, and treating diseases.